TerminatedPhase 4

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

Stopped: Protocol transitioned to standard of care, no funding available to continue support of research work or data analysis

United States33 participantsStarted 2017-11-21

Plain-language summary

This is a single center study for the donation of Hepatitis C Virus (HCV)-positive livers to HCV negative recipient patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Recipient is Age ≥ 18 years * Met Massachusetts General Hospital (MGH) transplant center criteria, listed for liver transplant * HCV naïve * Able to sign informed consent Exclusion Criteria: * Pregnant or nursing (lactating) women * Human immunodeficiency virus (HIV) positivity * Need for dual organ transplant * Any contra-indication to liver transplantation per center protocol

What they're measuring

Number of Participants With Undetectable Hepatitis C Virus (HCV) Viral RNA

Timeframe: 12 weeks post treatment

Trial details

NCT IDNCT03208127

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-06-04

Results submitted2022-05-20

View on ClinicalTrials.gov More End Stage Liver Disease trials